Overview Alexion is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Our marketed product Soliris® (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. We are also evaluating other potential...

Related "Licensing Agreements" Articles

OverviewAlexion is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Our marketed product Soliris®...

Danbury-based FuelCell Energy Inc. announced today that it is partnering with a South Korean power producer to sell the main components of its fuel cell generators in the country.
As part of the agreement, POSCO Power, an independent power producer based...

Abraham Giles was on his own when he told developers of property at Main and Trumbull streets that he had an agreement with the city to operate a parking lot at the site, the defense asserted today in Mayor Eddie A. Perez's corruption case.
It was this...